Medpace Holdings, Inc. (MEDP) · Oct 21, 2026 · Earnings

Medpace earnings beat; profit guidance rises, buyback doubles

Beat — Diluted EPS $4.84 vs ~$4.45 consensus

Medpace earnings beat Q3 estimates, margins expanded and 2026 profit guidance rose, while a new $1 billion buyback replaces the old authorization.

Medpace is a global clinical-research contractor serving biotech, pharmaceutical and medical-device customers; its current growth story is converting a growing backlog into revenue while preserving unusually high margins. The prior quarter already showed strong demand, with revenue up 17.2%, backlog up 4.9% and net new awards up 28.2% year over year.

The quarter beat a fairly demanding earnings bar. Revenue reached $716.0 million, modestly above the published consensus of roughly $714.4 million, while diluted EPS was $4.84 versus approximately $4.45 expected. That makes this a genuine earnings beat, although the revenue upside was narrow.

MetricQ3 2026Q3 2025 / expectationChange
Revenue$716.0M$659.9M / ~$714.4M consensus+8.5% YoY
Diluted EPS$4.84$3.86 / ~$4.45 consensus+25.4% YoY
EBITDA$172.1M$148.4M+16.0% YoY
EBITDA margin24.0%22.5%+150 bps
Backlog$3.167B$3.001B+5.6% YoY
Net new business awards$873.4M$789.6M+10.6% YoY
FY2026 revenue guidance$2.835B-$2.855BPrior: $2.805B-$2.885BNarrowed, midpoint unchanged
FY2026 diluted EPS guidance$17.97-$18.32Prior: $17.25-$17.95Raised

The more important signal is operating leverage. Revenue growth slowed from the first half’s faster pace, but EBITDA rose 16.0% and the margin expanded to 24.0% from 22.5%. That means Medpace is converting its backlog into profit more efficiently, not merely adding volume.

Backlog and bookings still support the growth runway, but the mix is not accelerating uniformly. Backlog increased 5.6% and net new awards rose to $873.4 million, both positive for future work. However, backlog growth remains slower than revenue growth, so the current pace depends on continued conversion of existing work and sustained bookings rather than a major expansion in contracted demand.

Management raised the profit outlook while tightening the revenue range. The new revenue midpoint is essentially unchanged from the prior forecast, so this is not a broad-based growth upgrade. The upgrade is concentrated in profitability: the midpoint of net income guidance rose from $504 million to $519 million, and diluted EPS guidance moved above the previous range.

The new buyback authorization adds capital-return capacity but is not an earnings driver yet. The company replaced the remaining $527 million authorization with a new $1.0 billion authorization through December 31, 2028. Because repurchases are discretionary and the guidance excludes buybacks after September 30, the immediate business change is limited; the main effect is greater flexibility to reduce the share count over time.

Bottom line: This was better than expected on earnings, with margin expansion and higher full-year profit guidance doing more work than the modest revenue beat. The business is advancing on a strong backlog and bookings base, while the larger buyback reinforces cash-generation confidence without changing the core operating story yet.

What to watch next

Q4 2026 results

Original filing on SEC EDGAR

Medpace earnings beat; profit guidance rises, buyback doubles | MEDP Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.